-
Abstract: There have been great insights into the biology of diffuse large B-cell lymphoma（DLBCL）over recent years,while progress in the therapeutic approach has been disappointing over the same time.In 2018,R-CHOP（rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisone）remains the "gold standard".Clinical trials are now in progress according to the molecular phenotype of the individual’s tumor.Many phase 1/2 studies have looked at adding targeted agents to conventional R-CHOP with some promise.The phase 3 data are now starting to emerge.This article sums up the molecular subgroups of DLBCL,interventional strategies,and the outcomes of these interventions to date.
-
Key words:
- diffuse large B-cell lymphoma /
- molecular subgroup /
- first-line therapy
-
-
[1] Swerdlow SH,Campo E,Pileri SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127:2375-2390.
[2] 黄耀慧,赵维莅.二代测序在弥漫大B细胞淋巴瘤中的应用[J].临床血液学杂志,2016,29(9):694-698.
[3] Tilly H,Gomes da Silva M,Vitolo U,et al.Diffuse large B-cell lymphoma (DLBCL):ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2015,26:v116-v125.
[4] Alizadeh AA,Eisen MB,Davis RE,et al.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J].Nature,2000,403:503-511.
[5] Pfeifer M,Grau M,Lenze D,et al.PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma[J].Proc Natl Acad Sci U S A,2013,110:12420-12425.
[6] Scott DW,Wright GW,Williams PM,et al.Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue[J].Blood,2014,123:1214-1217.
[7] Reinholz MM,Thompson D,Botros I,et al.Next generation sequencing for DLBCL classification[J].J Clin Oncol,2016,34:11559.
[8] Fisher RI,Gaynor ER,Dahlberg S,et al.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J].N Engl J Med,1993,328:1002-1006.
[9] Cunningham D,Hawkes EA,Jack A,et al.Rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma:a phase 3 comparison of dose intensification with 14-day versus 21-daycycles[J].Lancet,2013,381:1817-1826.
[10] Stiff PJ,Unger JM,Cook JR,et al.Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma[J].N Engl J Med,2013,369:1681-1690.
[11] Récher C,Coiffier B,Haioun C,et al.Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B):an open-label randomised phase 3 trial[J].Lancet,2011,378:1858-1867.
[12] Wilson WH,sin-Ho J,Pitcher BN,et al.Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma:CALGB/Alliance 50303[J].Blood,2016,128:496.
[13] van Imhoff GW,McMillan A,Matasar MJ,et al.Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma:the ORCHARRD study[J].J Clin Oncol,2016,35:544-551.
[14] Zelenetz AD,Mobasher M,Costa LJ,et al.Safety and efficacy of obinutuzumab (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma:results from the phase 2 gather study (GAO4915g)[J].Blood,2013,122:1820.
[15] Vitolo U,Trněny M,Belada D,et al.Obinutuzumab or Rituximab Plus Cyclophosphamide,Doxorubicin,Vincristine,and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma[J].J Clin Oncol,2017,35:3529-3537.
[16] Jacobsen ED,Sharman JP,Oki Y,et al.Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression[J].Blood,2015,125:1394-1402.
[17] Budde LH,Halwani A,Yasenchak CA,et al.Results of an ongoing phase 2 study of brentuximab vedotin with Rchp as frontline therapy in patients with high-intermediate/high-risk diffuse large B cell lymphoma (DLBCL)[J].Blood,2016,128:104.
[18] Ruan J,Martin P,Furman RR,et al.Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma[J].J Clin Oncol,2011,29:690-697.
[19] Davies AJ,Barrans S,Masihman T,et al.Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (DLBL):a prospective randomised study stratified by transcriptome profiling:REMoDL-B[J].Hematol Oncol,2017,35:130-131.
[20] Czuczman MS,Trneny M,Davies A,et al.Phase 2/3 multicenter,randomized,open-label study to compare the efficacy and safety of Lenalidomide versus Investigator's choice in patients with relapsed or refractory diffuse large B-Cell lymphoma[J].Clin Cancer Res,2017,23:4127-4137.
[21] Nowakowski GS,LaPlant B,Macon WR,et al.Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma:a phase II study[J].J Clin Oncol,2015,33:251-257.
[22] Wilson WH,Young RM,Schmitz R,et al.Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J].Nat Med,2015,21:922-926.
[23] Morschhauser F,Salles G,McKay P,et al.Interim report from a phase 2 multicentre study of tazemetostat,an EZH2 inhibitor,in patients with relapsed or refractory B-cell non-Hodgkin lymphomas[J].Hematol Oncol,2017,35:24-25.
[24] Lenz G,Hawkes E,Verhoef G,et al.Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)[J].J Clin Oncol,2017,35:7536.
[25] Johnston PB,LaPlant B,McPhail E,et al.Everolimus combined with R-CHOP-21 for new,untreated,diffuse large B-cell lymphoma (NCCTG 1085[Alliance]):safety and efficacy results of a phase 1 and feasibility trial[J].Lancet Haematol,2016,3:e309-e316.
[26] Davids MS,Roberts AW,Seymour JF,et al.Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma[J].J Clin Oncol,2017,35:826-833.
[27] Zelenetz AD,Salles G,Mason KD,et al.Results of a phase Ib study of venetoclax plus R-or G-CHOP in patients with B-cell non-Hodgkin lymphoma[J].Blood,2016,128:3032.
[28] Crump M,Leppä S,Fayad L,et al.Randomized,double-blind,phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma[J].J Clin Oncol,2016,34:2484-2492.
[29] Witzig TE,Tobinai K,Rigacci L,et al.PILLAR-2:A randomized,double-blind,placebo-controlled,phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL)[J].J Clin Oncol,2016,34:7506.
[30] Jaeger U,Trneny M,Melzer H,et al.Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission:results of the randomized NHL13 trial[J].Haematologica,2015,100:955-963.
[31] Thieblemont C,Tilly H,Gomes da Silva M,et al.Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisone[J].J Clin Oncol,2017,35:2473-2481.
[32] Georgiou K,Chen L,Berglund M,et al.Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas[J].Blood,2016,127:3026-3034.
[33] 金静霞,郑翠苹,陈丽雅,等.PD-1、PD-L1在弥漫大B细胞淋巴瘤组织中的差异性表达及其临床意义[J].临床血液学杂志,2018,31(1):34-37.
[34] Kiyasu J,Miyoshi H,Hirata A,et al.Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma[J].Blood,2015,126:2193-2201.
[35] Lesokhin AM,Ansell SM,Armand P,et al.Nivolumab in patients with relapsed or refractory hematologic malignancy:preliminary results of a phase Ib study[J].J Clin Oncol,2016,34:2698-2704.
-
计量
- 文章访问数: 56
- PDF下载数: 19
- 施引文献: 0
下载: